Human neutrophil activating peptide/interleukin 8 (NAP-1/IL-
Human neutrophil activating peptide/interleukin 8 (NAP-i/IL-8) is a 72 amino acid peptide which has been shown to activate neutrophils to degranulate and show respiratory burst in vitro,' 2 and to be chemotactic for neutrophils and lymphocytes in vitro and in vivo. 36 Neutrophils are a major source of enzymes, including those which degrade cartilage,7 and the accumulation of these cells in tissues is often observed in a variety of pathological conditions. These observations led us to examine circulating levels of the cytokine and antibodies directed against it in patients with rheumatoid arthritis (RA), and the development of a solid phase double ligand enzyme linked immunosorbent assay, 8 (ELISA) has enabled quantitative determinations of these parameters in serum samples.
Serum samples from 53 patients with definite or classical RA as defined by the American Rheumatism Association criteria9 were tested for NAP-1/IL-8 and antibodies to NAP-I/ IL-8. The clinical examinations were performed by a single observer.
The assay results were correlated with levels of quantified C reactive protein and with the number of arthritic joints, characterised by inflammation, pain, stiffness, swelling, and impairment. The levels of C reactive protein provide an objective index of disease activity in patients with RA, as high levels are associated with progressive disease, whereas the induction of clinical remission and control of the underlying disease process is associated with prompt normalisation of the level of C reactive protein. Similar background levels of antibodies to NAP-1 (0-106-0-296 absorption units) were detected in nine patients with RA who were either in complete remission or showing a significant improvement as a result of treatment. In patients with active disease, however, higher levels of antibody were detected. Figure  1 shows the highly significant relationship between levels of antibody to NAP-1 and quantified C reactive protein ( fig. IA ) and the number of arthritic joints in all patients ( fig   1B) . Table 2 gives the statistical correlations for these data. No significant correlation was seen between antibody levels and the duration of disease, and, similarly, there was no significant difference in titres of antibody to IL-8 between rheumatoid factor positive and negative patients. Figure 2 shows the titres for IgG antibody to NAP-1/IL-8 in serum samples from the same patients divided into treatment groups. There is a tendency towards higher antibody levels in the patients treated with immunosuppressive drugs and D-penicillamine. These drugs are generally regarded as second line treatment, used for patients where the disease appears to be resistant to initial treatment with gold or Reports of autoantibodies to cytokii relatively rare, although titres of antib interleukin 1 have been reported in a small proportion (17%) of patients with RA,'5 and Fomsgaard et al have described antibodies directed against tumour necrosis factor in patients with various rheumatic diseases.'6 These authors did not, however, show a correlation between antibody levels and disease severity, as is seen here.
Methods
The specific function of such circulating antibodies to cytokines is unclear. It has been speculated that they could represent a mechanism of cytokine regulation, acting as physiological carriers of the cytokine, or could fulfil an inhibitory role, neutralising unwanted activities. 7 It is possible that such a regulatory influence could be applied to NAP-1/IL-8. This cytokine has the potential to play a major I role in RA, as it appears to be produced at high concentrations in the affected joints of patients 
